Targeting tumor hypoxia in nasopharyngeal carcinoma

Head and Neck

Volumn 35, Issue 1, 2013, Pages 133-145

  Hong, Bo ^a   Lui, Vivian Wai Yan ^b   Hashiguchi, Masumi ^c   Hui, Edwin Pun ^a   Chan, Anthony Tak Cheung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c INTERNATIONAL CHRISTIAN UNIVERSITY   (Japan)

Author keywords

HIF 1 ; hypoxia; mechanism for carcinogenesis; nasopharyngeal cancer (NPC); targeted therapy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CISPLATIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXALIPLATIN;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL METABOLISM; CELL SURVIVAL; CLINICAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPOXIA; MEDLINE; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLICATION; RADIOSENSITIVITY; REVIEW; TREATMENT RESPONSE; TUMOR HYPOXIA; TUMOR VASCULARIZATION;

CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MOLECULAR TARGETED THERAPY; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS;

EID: 84871233667     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21877     Document Type: Review

References (142)

1. Chan AT, Teo PM, Johnson PJ,. Nasopharyngeal carcinoma. Ann Oncol 2002; 13: 1007-1015.
2. Tao Q, Chan AT,. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007; 9: 1-24. (Pubitemid 47398642)
3. Spano JP, Busson P, Atlan D, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer 2003; 39: 2121-2135. (Pubitemid 37297736)
4. Li H, Ahonen TJ, Alanen K, et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004; 64: 4774-4782. (Pubitemid 38924520)
5. Agulnik M, Siu LL,. State-of-the-art management of nasopharyngeal carcinoma: current and future directions. Br J Cancer 2005; 92: 799-806. (Pubitemid 40462620)
6. Skinner DW, Van Hasselt CA, Tsao SY,. Nasopharyngeal carcinoma: modes of presentation. Ann Otol Rhinol Laryngol 1991; 100: 544-551.
7. Isobe K, Ito H, Shigematsu N, et al. Advanced nasopharyngeal carcinoma treated with chemotherapy and radiotherapy: distant metastasis and local recurrence. Int J Oncol 1998; 12: 1183-1187. (Pubitemid 28186785)
8. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005; 97: 536-539. (Pubitemid 40590436)
9. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY,. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-637.
10. Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005; 23: 8461-8468.
11. Ma BB, Lui VW, Hui EP, et al. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs 2010; 28: 413-420.
12. Wong JH, Lui VW, Umezawa K, et al. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett 2010; 287: 23-32.
13. Sung FL, Poon TC, Hui EP, et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. In Vivo 2005; 19: 237-245.
14. Wang SS, Guan ZZ, Xiang YQ, Jiang WQ, Lin TY, Zhang L,. [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts]. Ai Zheng 2004; 23 (Suppl 11): 1365-1369.
15. Hsu CH, Gao M, Chen CL, Yeh PY, Cheng AL,. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology 2005; 68: 538-547. (Pubitemid 41160987)
16. Lui VW, Lau CP, Ho K, et al. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Invest New Drugs 2011; 29: 1241-1252.
17. Hui EP, Lui VW, Wong CS, et al. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs 2011; 29: 1123-1131.
18. Lui VW, Yau DM, Wong EY, et al. Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 2009; 30: 2085-2094.
19. Xiao X, Wu J, Zhu X, et al. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 2007; 121: 2095-2104. (Pubitemid 47463175)
20. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23: 3568-3576.
21. Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J, Au GK,. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008; 30: 863-867. (Pubitemid 352008945)
22. Ma B, Hui EP, King A, et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol 2008; 62: 59-64. (Pubitemid 351537846)
23. Ma BB, Hui EP, Chan AT,. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci 2008; 99: 1311-1318. (Pubitemid 351761718)
24. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-3773. (Pubitemid 47372619)
25. Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996; 23: 1378-1383.
26. Zheng YJ, Fan W, Zhao C, Yang XC, Cui NJ, Chen FJ,. [Clinical application of 99mTc-HL91 hypoxia imaging in nasopharyngeal carcinoma]. Ai Zheng 2006; 25: 378-381.
27. Zheng YJ, Zhao C, Fan W, Liu H, Cui NJ, Chen FJ,. [Changes of hypoxia in primary lesion of nasopharyngeal carcinoma during the treatment course and the clinical value thereof]. Zhonghua Yi Xue Za Zhi 2007; 87: 2698-2702.
28. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-943. (Pubitemid 26065381)
29. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW,. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289. (Pubitemid 27318643)
30. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26: 45-50. (Pubitemid 23063609)
31. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P,. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-4515. (Pubitemid 26330463)
32. Janssen HL, Haustermans KM, Balm AJ, Begg AC,. Hypoxia in head and neck cancer: how much, how important? Head Neck 2005; 27: 622-638. (Pubitemid 40961072)
33. Brown JM,. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002; 1: 453-458.
34. Munn LL,. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003; 8: 396-403. (Pubitemid 36442691)
35. Murphy BJ, Laderoute KR, Chin RJ, Sutherland RM,. Metallothionein IIA is up-regulated by hypoxia in human A431 squamous carcinoma cells. Cancer Res 1994; 54: 5808-5810. (Pubitemid 24375210)
36. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP,. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62: 3387-3394. (Pubitemid 34651384)
37. Nordsmark M, Overgaard M, Overgaard J,. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31-39. (Pubitemid 26396294)
38. Nordsmark M, Overgaard J,. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000; 57: 39-43.
39. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24. (Pubitemid 41503384)
40. Rofstad EK, Sundfor K, Lyng H, Trope CG,. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000; 83: 354-359. (Pubitemid 30453576)
41. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998; 48: 149-156. (Pubitemid 28423786)
42. Brown JM,. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59: 5863-5870. (Pubitemid 30004940)
43. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18]fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12: 5435-5441. (Pubitemid 44497258)
44. Liu S, Xue Y, Zhang H, et al. [Preliminary study on the value of 99Tc(m)-HL91 imaging in predicting sensitivity to radiotherapy in patients with nasopharyngeal carcinoma]. Zhonghua Zhong Liu Za Zhi 2007; 29: 369-372.
45. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002; 8: 2595-2604. (Pubitemid 34856346)
46. Hui EP, Sung FL, Yu BK, et al. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res 2008; 14: 7080-7087.
47. Xueguan L, Xiaoshen W, Yongsheng Z, Chaosu H, Chunying S, Yan F,. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol (R Coll Radiol) 2008; 20: 606-612.
48. Mai HQ, Zeng ZY, Zhang CQ, et al. Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer 2006; 106: 1548-1553.
49. Chan CM, Ma BB, Hui EP, et al. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma-a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. Oral Oncol 2007; 43: 373-378. (Pubitemid 46415794)
50. Li YH, Hu CF, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 2008; 6: 1 (abstract).
51. Sung FL, Hui EP, Tao Q, et al. Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett 2007; 253: 74-88. (Pubitemid 46881199)
52. Niedobitek G,. The Epstein-Barr virus: a group 1 carcinogen? Virchows Arch 1999; 435: 79-86. (Pubitemid 29397023)
53. Ogino T, Moriai S, Ishida Y, et al. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 2007; 120: 2401-2410. (Pubitemid 46642127)
54. Lui VW, Wong EY, Ho Y, et al. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 2009; 125: 1884-1893.
55. Kondo S, Seo SY, Yoshizaki T, et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res 2006; 66: 9870-9877. (Pubitemid 44672038)
56. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS,. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 2004; 24: 5223-5234. (Pubitemid 38738158)
57. O'Neil JD, Owen TJ, Wood VH, et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol 2008; 89: 2833-2842.
58. Hong B, Lui VW, Hui EP, et al. Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. Invest New Drugs 2011; 29: 401-410.
59. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK,. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12: 363-369. (Pubitemid 32685637)
60. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-1545. (Pubitemid 30183422)
61. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14: 391-396. (Pubitemid 30131884)
62. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL,. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004. (Pubitemid 32476461)
63. Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA,. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 2004; 25: 2089-2100. (Pubitemid 39534845)
64. McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM,. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 2006; 281: 24171-24181. (Pubitemid 44274191)
65. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L,. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J 2003; 370: 1011-1017. (Pubitemid 36399095)
66. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T,. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 2002; 512: 157-162. (Pubitemid 34164471)
67. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW,. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003; 9: 2416-2425. (Pubitemid 36842080)
68. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM,. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-361. (Pubitemid 38340304)
69. Hsiao SH, Lee MS, Lin HY, et al. Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma. Acta Otolaryngol 2009; 129: 1519-1523.
70. Huang YT, Sheen TS, Chen CL, et al. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res 1999; 59: 1599-1605.
71. Triesscheijn M, Baas P, Schellens JH, Stewart FA,. Photodynamic therapy in oncology. Oncologist 2006; 11: 1034-1044. (Pubitemid 44564813)
72. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ,. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000; 60: 4066-4069. (Pubitemid 30636586)
73. Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B,. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol 2005; 56: 569-577. (Pubitemid 41425052)
74. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003; 9: 59-67. (Pubitemid 36109716)
75. Nelson J, Bagnato A, Battistini B, Nisen P,. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110-116. (Pubitemid 37328878)
76. Hong B, Lui VW, Hui EP, et al. Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochem Pharmacol 2010; 79: 842-852.
77. Zhou J, Schmid T, Schnitzer S, Brune B,. Tumor hypoxia and cancer progression. Cancer Lett 2006; 237: 10-21.
78. Gupta M, Gupta SK, Hoffman B, Liebermann DA,. Gadd45a and Gadd45b protect hematopoietic cells from UV-induced apoptosis via distinct signaling pathways, including p38 activation and JNK inhibition. J Biol Chem 2006; 281: 17552-17558. (Pubitemid 44035554)
79. Koong AC, Denko NC, Hudson KM, et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000; 60: 883-887. (Pubitemid 30129520)
80. Sonna LA, Cullivan ML, Sheldon HK, Pratt RE, Lilly CM,. Effect of hypoxia on gene expression by human hepatocytes (HepG2). Physiol Genomics 2003; 12: 195-207. (Pubitemid 37139699)
81. Denko NC, Fontana LA, Hudson KM, et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003; 22: 5907-5914. (Pubitemid 37176711)
82. Mazure NM, Pouyssegur J,. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol 2010; 22: 177-180.
83. Pouyssegur J, Dayan F, Mazure NM,. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-443. (Pubitemid 44050138)
84. Brahimi-Horn MC, Chiche J, Pouyssegur J,. Hypoxia and cancer. J Mol Med 2007; 85: 1301-1307. (Pubitemid 50004093)
85. Cosse JP, Rommelaere G, Ninane N, Arnould T, Michiels C,. BNIP3 protects HepG2 cells against etoposide-induced cell death under hypoxia by an autophagy-independent pathway. Biochem Pharmacol 2010; 80: 1160-1169.
86. Wu MX,. Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. Apoptosis 2003; 8: 11-18. (Pubitemid 36133133)
87. Zhang YQ, Herman B,. Expression and modification of ARC (apoptosis repressor with a CARD domain) is distinctly regulated by oxidative stress in cancer cells. J Cell Biochem 2008; 104: 818-825. (Pubitemid 351830832)
88. Erler JT, Giaccia AJ,. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 2006; 66: 10238-10241. (Pubitemid 44799737)
89. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226.
90. Lin MT, Kuo IH, Chang CC, et al. Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion. J Biol Chem 2008; 283: 15807-15815.
91. Dimova EY, Moller U, Herzig S, et al. Transcriptional regulation of plasminogen activator inhibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible factor-1 in HepG2 cells. Thromb Haemost 2005; 93: 1176-1184. (Pubitemid 40823525)
92. Schilling D, Bayer C, Geurts-Moespot A, et al. Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. BMC Cancer 2007; 7: 143 (abstract).
93. Liu G, Shuman MA, Cohen RL,. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995; 60: 501-506.
94. Brooks TD, Slomp J, Quax PH, et al. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clin Exp Metastasis 2000; 18: 445-453. (Pubitemid 32844246)
95. Sugiura Y, Ma L, Sun B, et al. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res 1999; 59: 1327-1336. (Pubitemid 29136266)
96. Isogai C, Laug WE, Shimada H, et al. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 2001; 61: 5587-5594. (Pubitemid 32700275)
97. Speleman L, Kerrebijn JD, Look MP, Meeuwis CA, Foekens JA, Berns EM,. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck 2007; 29: 341-350. (Pubitemid 46623499)
98. Chambers SK, Ivins CM, Carcangiu ML,. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998; 79: 449-454. (Pubitemid 28445264)
99. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-643. (Pubitemid 30094561)
100. Zheng X, Jiang F, Katakowski M, et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci 2007; 98: 674-684. (Pubitemid 46563443)
101. Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T,. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2008; 295: G709-G717.
102. Rofstad EK, Halsor EF,. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer 2002; 86: 301-308. (Pubitemid 34185162)
103. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613. (Pubitemid 26272112)
104. Roberts WG, Palade GE,. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997; 57: 765-772. (Pubitemid 27085664)
105. Feng BC, Liu KL,. A morphological study of stromal microvasculature of nasopharyngeal precancerous lesions. Chin Med J (Engl) 1991; 104: 422-424.
106. Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006; 1: e116.
107. Keleg S, Kayed H, Jiang X, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer 2007; 121: 21-32. (Pubitemid 46759489)
108. Ishikawa T, Chen J, Wang J, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003; 22: 1238-1242. (Pubitemid 36363387)
109. Wen QL, Meng MB, Yang B, et al. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 2009; 100: 1510-1519.
110. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
111. Gatenby RA, Gillies RJ,. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-899. (Pubitemid 39472955)
112. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ,. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14: 176-186. (Pubitemid 26074280)
113. Yeung HY, Lai KP, Chan HY, Mak NK, Wagner GF, Wong CK,. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology 2005; 146: 4951-4960. (Pubitemid 41446634)
114. Chang AC, Jellinek DA, Reddel RR,. Mammalian stanniocalcins and cancer. Endocr Relat Cancer 2003; 10: 359-373. (Pubitemid 37267555)
115. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000; 18: 1351-1359. (Pubitemid 30159856)
116. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005; 23: 79-87. (Pubitemid 41702625)
117. Treat J, Johnson E, Langer C, et al. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1998; 16: 3524-3527. (Pubitemid 28506763)
118. Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28: 2989-2995.
119. Williamson SK, Crowley JJ, Lara PN Jr, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005; 23: 9097-9104.
120. Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52: 769-778. (Pubitemid 34158740)
121. Patterson LH, McKeown SR, Ruparelia K, et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 2000; 82: 1984-1990. (Pubitemid 30326460)
122. Papadopoulou MV, Bloomer WD, Hollingshead MG,. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts. Anticancer Res 2005; 25: 1865-1869. (Pubitemid 40904578)
123. Seow HA, Penketh PG, Shyam K, Rockwell S, Sartorelli AC,. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carb onyl]hydrazine: an anticancer agent targeting hypoxic cells. Proc Natl Acad Sci U S A 2005; 102: 9282-9287. (Pubitemid 40923555)
124. Brown JM,. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993; 67: 1163-1170. (Pubitemid 23172847)
125. Xu P, Huang JM, Ren Y, et al. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells. Chin J Cancer 2010; 29: 126-130.
126. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-520. (Pubitemid 27198648)
127. Greco O, Marples B, Joiner MC, Scott SD,. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 2003; 197: 312-325. (Pubitemid 37487030)
128. Cowen RL, Williams KJ, Chinje EC, et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 2004; 64: 1396-1402. (Pubitemid 38235608)
129. Zhong Y, Tang YY, Xie CN, Zhao SP,. [Killing effect improved by fusion gene HRE1.Egr-1. yCDglyTK on gene-radio therapy of nasopharyngeal cancer in vitro]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008; 33: 110-114.
130. Mizuno T, Nagao M, Yamada Y, et al. Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther 2006; 13: 131-140. (Pubitemid 43113414)
131. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G,. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004; 3: 233-244. (Pubitemid 39193698)
132. Koh MY, Spivak-Kroizman T, Venturini S, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008; 7: 90-100.
133. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95: 516-525.
134. Shin DH, Kim JH, Jung YJ, et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 2007; 255: 107-116. (Pubitemid 47212610)
135. Chen CJ, Hsu MH, Huang LJ, et al. Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem Pharmacol 2008; 75: 360-368.
136. Won MS, Im N, Park S, et al. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochem Biophys Res Commun 2009; 385: 16-21.
137. Narita T, Yin S, Gelin CF, et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res 2009; 15: 6128-6136.
138. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-257.
139. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004; 6: 33-43. (Pubitemid 38903160)
140. Wong TS, Chan WS, Li CH, et al. Curcumin alters the migratory phenotype of nasopharyngeal carcinoma cells through up-regulation of E-cadherin. Anticancer Res 2010; 30: 2851-2856.
141. Choi H, Chun YS, Kim SW, Kim MS, Park JW,. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol 2006; 70: 1664-1671.
142. Robertson N, Potter C, Harris AL,. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004; 64: 6160-6165. (Pubitemid 39129417)